News Agency
Men's Weekly

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC

  • Written by PR Newswire

HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) locally advanced or metastatic non-small cell...

Read more: Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF)...

Australian Workplaces 2026: Why Office Furniture Stools Are Gaining Ground in Modern Design

Sydney, Australia — 2026 — As Australian workplaces continue to evolve at a rapid pace, a once-overlooked piece of furniture is stepping into the spotlight: the stool. From drafting stools in design studios to height-adjustable seating in schools and laboratories... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion